Canada Generic Drug Market – Share, Size, Growth, Trends, Industry Analysis And Outlook 2017 – 2022

The Canada generic drug market has witnessed a significant growth over the past several years, reaching a volume of around 0.46 Billion Units in 2016. This can be attributed to public and private sector drugs programs and healthcare initiatives promoting the use of generic drugs.

Canada currently represents the ninth-largest generic drug market worldwide, accounting for nearly 3% of the total global share. The share of generic drugs in the pharmaceuticals market has increased significantly over the past several years. At present, generic drugs account for around 70% of the total retail prescriptions, and 22% of the total pharmaceutical sales value in the region. This can be attributed to the various public and private sector drug programs aimed at cost-containment and increasing awareness about generic drugs. The latest report by IMARC Group titled, “Canada Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022”, finds that the Canada generic drug market reached a volume of around 0.46 Billion Units in 2016, growing at a CAGR of around 8% during 2010-2016.

Get Sample of the Report: http://www.imarcgroup.com/request?type=report&id=700&flag=B

Highlights of the Canada Generic Drug Market:

Generic drugs account for nearly 70% of the total retail prescriptions in Canada.
Changing demographics and government initiatives are the major growth drivers.
Patent expiry of a number of blockbuster drugs is expected to provide growth opportunities.

Population growth, changing demographics, increasing prevalence of chronic diseases and a rise in the use of drug therapy are projected to put more pressure on Government healthcare initiatives such as the ‘drug benefit plans’ operative in the Canadian territories and provinces. As the sustainability of these programmes is largely dependent on the use of generic drugs, the demand for these drugs is expected to increase over the next several years. Moreover, the patent expiry of a number of blockbuster drugs is also anticipated to expand the generic drug market in Canada. According to the report, the market is further expected to reach a volume of nearly 0.7 Billion Units by 2022.

Browse full report with TOC @ http://www.imarcgroup.com/canada-generic-drug-market

The report analyses the competitive landscape of the market and provides details of the major players in the market. Some of these include Teva Pharmaceutical Ltd., Apotex Inc., Snadoz Canada, Actavis, Mylan, Pharmascience Inc., Taro Pharmaceuticals, Novartis, Ranbaxy Pharmaceuticals Canada and Hospira. The report provides a comprehensive insight into the historical and current trends as well as the future prospects of the generic drug market in Canada. This study serves as an exceptional tool to understand the sales trends, volume trends, growth, key segments, competitive structure, regulations, major manufacturer, major distributors, top drugs, manufacturing requirements, opportunities and future prospects of the Canada generic drug market. This report can serve as an excellent guide for manufacturers, consultants, researchers, marketing strategists and all those who plan to foray into the Canada generic drug market in any form.

Find more reports on healthcare industry @ http://www.imarcgroup.com/categories/healthcare-market-research-reports

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us

IMARC Group
USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: http://www.imarcgroup.com
Follow us on twitter: @imarcglobal

Global Biopharmaceutical Market to Grow at 8% During 2016-2021 With Manufacturers Turning to Untapped Regions

Image result for biopharmaceutical

In order to expand and diversify their operations outside their core markets, biopharmaceutical giants are trying to penetrate emerging markets by collaborating with local pharmaceutical companies or setting up their manufacturing facilities in these regions.

IMARC’s latest report Global Biopharmaceutical Market Report & Forecast (2016-2021)” provides an in-depth analysis of the global biopharmaceutical market along with a comprehensive study of market trends, geographical structure, therapeutic structure, competitive structure and market outlook. Biopharmaceuticals are large, complex molecules extracted from biological sources such as yeast, E. coli and mammalian cell cultures. Currently, the applications of biopharmaceuticals are increasing as they have high efficiency, limited generic threat, are target oriented and can be used to treat ailments such as cancers and autoimmune diseases. Biopharmaceuticals also have a higher approval rate compared to small molecule drugs and have a very strong tendency to achieve blockbuster status. According to the report, the global biopharmaceutical market was valued at nearly US$ 160 Billion in 2015, growing at a CAGR of 9% during 2008-2015.  The market is expected to grow a CAGR of nearly 8% during 2016-2021 as a result of the rising prevalence of chronic diseases such as diabetes, autoimmune diseases, cancers etc., an ageing global population and a significant number of monoclonal antibodies in the pipeline.

Browse full report at: http://www.imarcgroup.com/biotechnology-industry

The report has segmented the market on the basis of key regions. As a result of scientific advancements and research facilities, the biopharmaceutical market is largely concentrated in the United States and Western Europe with the United States representing the world’s largest biopharmaceutical market. However, the growth rates in these markets are expected to decline as both the government and private insurance providers are likely to apply cost containment measures. Consequently, biopharmaceutical giants are focussing on emerging markets such as China, Brazil, India, Russia, Turkey, South Korea and Mexico in order to expand their business. The huge population of these regions along with rising incomes, expanding health insurance coverage and increasing demand for top-shelf medical treatments is expected to drive the global biopharmaceutical market in these regions.

The report has further segmented this market on the basis of various biopharmaceutical classes. Recombinant proteins currently represent the biggest segment of the biopharmaceutical market accounting for the majority of the global sales. Recombinant proteins were followed by monoclonal antibodies and purified proteins. Monoclonal antibodies, on the other hand, are expected to be the fastest growing class. The report has further analysed the competitive landscape of this market. Some of the key players included in the report are – Roche, Amgen, Novo Nordisk, AbbVie, Sanofi, Johnson & Johnson, etc.

Enquiry for sample report or more details, click here: http://www.imarcgroup.com/enquiry-form/

 

Contact Us

IMARC Group
Tel: +91-120-415-5099
USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: http://www.imarcgroup.com
Follow us on twitter: @imarcglobal

US Generics Market: Industry Trends and Opportunities

A number of factors have catalyzed the strong growth in the US generics market. This includes their low costs, drug patent expiries, cost savings for  governments’ and payers’, lower copayments for patients, ageing population and an increasing prevalence of chronic diseases.

US Generics Market

The United States represents the world’s biggest market for generic drugs. Over the past three decades, the acceptance and use of generics in the United States has changed markedly. This transformation has been catalyzed by a number of factors. The continuous expiration of drug patents, rising aging population, increasing prevalence of chronic diseases and continuous efforts by governments and health care service providers to control their healthcare expenditures have enabled generics to represent a multi billion dollar industry in the United States.

The report entitled “US Generics Market: Industry Trends, Competitive Landscape, Opportunities and Outlook” represents an in-depth analysis on the historical, current and future trends in the US generics market. This research report serves as an exceptional tool to understand the drivers, sales trends, prescription trends, market structure, competitive landscape, regulations, key players, key drugs, manufacturing and the outlook of the US generics market. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who want to gain an insight into the US generics market in any form.

Key Questions Answered:

  • What are generic drugs and how are they different from branded drugs?
  • How have the US generics market performed in recent years?
  • How have generics performed compared to branded drugs?
  • What were the total sales and prescriptions for generics in the US?
  • Who are the key players in the US generics market and how have they performed?
  • What is the structure of the US generics market?
  • Which are the most prescribed generics in the US?
  • What is the pricing mechanism of generics in the US?
  • What is the value chain of generics in the US?
  • What are the regulations for generics in the US?
  • How are generics distributed in the US?
  • How are generics manufactured?
  • What are the raw material and machinery requirements to manufacture generics?
  • What are the drivers and challenges in the US generics market?

Read Full Report on US Generics Market: http://www.imarcgroup.com/us-generics-market

Contact Us
IMARC Group
Email: Sales@imarcgroup.com
Website: http://www.imarcgroup.com/
LinkedIn: http://www.linkedin.com/company/imarc-group
Twitter: @IMARCGlobal
Contact No: +91-120-415-5099

Cancer Generics Market: Industry Trends, Growth, Manufacturing Process, Machinery Requirements, Incomes and Profits

This report provides an insight into the cancer generics market and the requirements to setup and run a cancer generic manufacturing plant (both tablets and injectables). Factors such as capital cost, raw material requirements, machinery requirements, incomes, expenditures, etc. Have been thoroughly analysed in this report

 This report explores the cancer generics market and provides the know-how to start and run a cancer generic drug manufacturing plant. The report finds that cancer generics have a higher entry barrier and product differentiation compared to conventional generics. This has resulted in a lower competitive intensity enabling them to be priced higher with substantially bigger margins.

Generic Oncology Drug Market

IMARC’s latest study “Generic Oncology Drug Manufacturing Plant Project Report: Industry Trends, Manufacturing Process, Machinery, Raw Materials, Cost and Revenue” provides a comprehensive roadmap for stakeholders who are planning to setup and run a generic oncology drug manufacturing plant. Aspects such as market size, industry trends, manufacturers, land, construction, machinery, labour, investments, revenues, rate of return, margins, etc. have been thoroughly covered in this report.

Key Questions Answered in This Report?

  • What is the key success and risk factors in the generic oncology drug industry?
  • How has the global generic oncology drug market performed so far and how will it perform in the coming years?
  • What is the structure of the generic industry and who are the key players?
  • What are the various unit operations involved in a generic oncology drug manufacturing plant?
  • What is the total size of land required for setting up a generic oncology drug manufacturing plant?
  • What are the machinery requirements for setting up a generic oncology drug manufacturing plant?
  • What are the raw material requirements for setting up a generic oncology drug manufacturing plant?
  • What are the utility requirements for setting up a generic oncology drug manufacturing plant?
  • What are the manpower requirements for setting up a generic oncology drug manufacturing plant?
  • What are the infrastructure costs for setting up a generic oncology drug manufacturing plant?
  • What are the capital costs for setting up a generic oncology drug manufacturing plant?
  • What are the operating costs for setting up a generic oncology drug manufacturing plant?
  • What will be the income and expenditures for a generic oncology drug manufacturing plant?
  • What is the time required to break-even?

To buy the complete report or to get a free sample, please contact:

IMARC Group Asia:

Email: apac@imarcgroup.com
Phone: +91-120-415-5099

IMARC Group North America:

Email: america@imarcgroup.com
Phone: +1-631-791-1145

IMARC Group Europe, Middle East & Africa:

Email: ema@imarcgroup.com
Phone: +44-702-409-7331

To know more please visit: http://www.imarcgroup.com/generic-oncology-drug-manufacturing-plant

Growth in the Biopharmaceutical Industry Driving the Demand for Cold Chain Packaging and Transportation Services

Any excursions in the ideal storage or transportation temperatures of biopharmaceuticals can disrupt their protein structure and make them ineffective. This has created a huge demand for efficient cold chain logistics services in the biopharmaceutical industry.

IMARC Group’s latest report titled, “Global Healthcare Cold Chain Logistics Market Report and Forecast (2016-2020)” finds that the global biopharmaceuticals market was worth US$ 136 Billion in 2014 and is expected to experience a healthy growth rate in the future. According to the report, the key factors that contributed to the growth of the biopharmaceuticals industry are the significantly higher potency and efficacy of biopharmaceuticals compared to small molecule drugs, the ability of these products to be tailored as per the individual needs of a patient, higher approval success rates and significantly higher cost of therapy compared to traditional medications.

Healthcare Cold Chain Logistics Market

The report finds that most biopharmaceuticals are protein based drugs and highly sensitive to temperature changes. As such, these drugs are recommended to be stored and transported at temperatures ranging from 2°- 8°C. Any excursions in their ideal storage or transportation temperatures can disrupt their protein structure and make them ineffective. This has created a huge demand for efficient cold chain logistics services in the biopharmaceuticals industry. According to the report, the key factors driving the market for biopharmaceutical cold chain logistics services are the entry of biosimilars or generic versions of biological drugs which have already been launched in the US, Europe and other major healthcare markets, the increase in outsourcing trends of biopharmaceutical manufacturing to offshore locations and the fact that biopharmaceutical manufacturing plants are concentrated in a few regions and their end-use markets diversified across the globe.

The report has analysed the opportunities for cold chain logistics services not only in the biopharmaceutical industry but also in the clinical trial materials and vaccines industries. This report also gives an insight into the market trends, market segments, regional breakup, challenges, global trade scenario and the key players in the global healthcare cold chain logistics industry. The report, which is based on both desk based research and multiple waves of primary research is a must read for anyone who plans to venture into the healthcare cold chain logistics services industry.

To buy the complete report or to get a free sample, please contact:

IMARC Group Asia:
Email: apac@imarcgroup.com
Phone: +91-120-415-5099

IMARC Group North America:
Email: america@imarcgroup.com
Phone: +1-631-791-1145

IMARC Group Europe, Middle East & Africa:
Email:ema@imarcgroup.com
Phone: +44-702-409-7331

To know more on healthcare cold chain logistics market visit: http://www.imarcgroup.com/healthcare-cold-chain-logistics-market

China Diabetes Market: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics

Driven by a large diabetic population, continuous economic growth and increasing disposable incomes, the diabetes market – Non-Insulin Anti-diabetics, Insulin and Diabetes Diagnostics is witnessing double digit growth rates.

As the second largest economy of the world, China enjoys pink of health but its affluence is giving rise to another sickness – a rapid increase in a life-style disease called diabetes. With the Chinese population getting richer, fatter and less mobile, there has been a surge in the prevalence of diabetes. With a prevalence rate of around 12 percent in the adult population, China currently represents the diabetes capital of the world.

The rising prevalence of diabetes, however, is catalysing the market for diabetes products in the country. Driven by a continuous economic growth and increasing disposable incomes, the diabetes market – Non-Insulin Anti-diabetics, Insulin and Diabetes Diagnostics is witnessing double digit growth rates and creating lucrative opportunities for global pharmaceutical and diagnostic companies at a time when growth rates in the more developed markets have declined.

China Diabetes Market

IMARC’s new report “China Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics” provides an analytical and statistical insight into the China diabetes market. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in China. The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the Chinese diabetes market. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the Chinese diabetes market in any form.

What we have achieved in this report:

Comprehensive situation analysis of the Chinese diabetes epidemiology and its dynamics:

Focus of the Analysis:

  • Historical, current and future prevalence of diabetes in China
  • Historical, current and future prevalence of type-1 and type-2 diabetes in China
  • Historical, current and future prevalence of diabetes in the urban and rural regions in China
  • Historical, current and future prevalence of diabetes among males and females in China
  • Historical, current and future prevalence of diabetes among various age groups in China
  • Historical, current and future diagnosis rates for diabetes in China
  • Historical, current and future drug treatment rates for diabetes in China

Comprehensive situation analysis of the Chinese Oral Antidiabetics market and its dynamics:

Focus of the Analysis:

  • Performance of the Oral Antidiabetics market in China
  • Performance of key classes
  • Performance of key players
  • Market outlook

Comprehensive situation analysis of the Chinese Insulin market and its dynamics:

Focus of the Analysis:

  • Performance of the Insulin market in China
  • Performance of key classes
  • Performance of key players
  • Market outlook

Comprehensive situation analysis of the Chinese diabetes diagnostics market and its dynamics:

Focus of the Analysis:

  • Performance of the diabetes diagnostics market in China
  • Market segmentation
  • Key players
  • Market outlook

To buy the complete report or to get a free sample, please contact:

IMARC Group Asia:
Email: apac@imarcgroup.com
Phone: +91-120-415-5099

IMARC Group North America:
Email: america@imarcgroup.com
Phone: +1-631-791-1145

IMARC Group Europe, Middle East & Africa:
Email: ema@imarcgroup.com
Phone: +44-702-409-7331

To know more please visit: http://www.imarcgroup.com/china-diabetes-market

Global Nutraceuticals Market Exhibiting Strong Growth

Nutraceuticals are currently driving an emerging trend of “Personalized Nutrition” whereby food and drinks products are more closely matched to consumers’ individual health and nutritional needs, aspirations and preferences.

Nutraceuticals are nutritional or ‘functional foods’ that are demonstrated to have a physiological benefit or provide relief from various diseases and ailments. They have become extremely attractive for food and beverage companies due to their high margins and minimal regulatory requirements.

Nutraceuticals are currently driving an emerging trend of “Personalized Nutrition” whereby food and drinks products are more closely matched to consumers’ individual health and nutritional needs, aspirations and preferences. This emerging trend is having immense possibilities and opportunities for producers and marketers of Personalized Nutrition Products. Some of the key factors behind the sustained growth of this market have been an increasing aging population, rising disposable incomes, changing lifestyles, increasing awareness, a growing trend of health & wellness and emerging new markets in developing countries. These factors are expected to keep on driving the market in the coming years.

nutraceuticals market

The report “Nutraceuticals Market Report: COQ10, Probiotics/Prebiotics, Taurine, Omega-3, Green Tea, Antioxidants, Calcium, Lycopene, B-Complex, Dietary Fiber, Collagen, Aloe Vera and Zinc” provides a comprehensive insight into the global nutraceuticals market. The study that has been undertaken using both desk based and qualitative primary market research has analyzed various aspects of the global nutraceuticals market, viz. key nutrients for food/beverage fortification, clinical trials, consumer perspectives, market trends and future growth prospects.

What we have achieved in this report:

Comprehensive Analysis of Key Nutrients for Food and Beverage Fortification

Nutrients Covered: COQ10, Probiotics/Prebiotics, Taurine, Omega-3, Green Tea, Antioxidants, Calcium, Lycopene, B-Complex, Dietary Fiber, Collagen, Aloe Vera and Zinc

Focus of the Analysis:

  • Analytical description of clinical trials suggesting health benefits of these nutrients across various indications
  • Findings of surveys conducted for understanding consumer awareness, perspective and behavior towards nutraceutical

Comprehensive Market Analysis of the Global Nutraceuticals Market

Focus of the Analysis:

  • Current trends and future prospects of nutraceuticals
  • Current trends and future prospects across various product categories and indications
  • Current trends and future prospects of personalized foods
  • Current trends and future prospects of personalized beverages
  • New product launches
  • Market drivers and challenges
  • Opportunities across various indications

Market Analysis Across Major Global Markets

Countries Covered: United States, Germany, United Kingdom, France, Spain, Italy, Japan, China, Russia, India, Brazil and Mexico

Focus of the Analysis:

  • Market overview
  • Current and historical market trends
  • Market by indication
  • Market forecast

To buy the complete report or to get a free sample, please contact:

IMARC Group Asia:
Email: apac@imarcgroup.com
Phone: +91-120-415-5099

IMARC Group North America:
Email: america@imarcgroup.com
Phone: +1-631-791-1145

IMARC Group Europe, Middle East & Africa:
Email: ema@imarcgroup.com
Phone: +44-702-409-7331

To know more please visit: http://www.imarcgroup.com/nutraceuticals-market